2009
Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia
Krystal JH, Tolin DF, Sanacora G, Castner SA, Williams GV, Aikins DE, Hoffman RE, D'Souza DC. Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia. Drug Discovery Today 2009, 14: 690-697. PMID: 19460458, PMCID: PMC2898127, DOI: 10.1016/j.drudis.2009.05.002.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAnxiety DisordersDrug Delivery SystemsHumansMood DisordersMulticenter Studies as TopicNeuronal PlasticityPharmaceutical PreparationsSchizophreniaConceptsPsychiatric disordersSymptomatic reliefMood disordersAnxiety disordersNeuroplasticity deficitsCurrent pharmacotherapyUnderlying abnormalityCurrent treatmentPsychiatric treatmentNeuroplasticityDisordersPharmacotherapyTreatmentExciting new findingsSchizophreniaReliefAbnormalitiesNeurodevelopmentNew findingsPrevention
2005
GABA and glutamate systems as therapeutic targets in depression and mood disorders
Kendell SF, Krystal JH, Sanacora G. GABA and glutamate systems as therapeutic targets in depression and mood disorders. Expert Opinion On Therapeutic Targets 2005, 9: 153-168. PMID: 15757488, DOI: 10.1517/14728222.9.1.153.Peer-Reviewed Original Research